Literature DB >> 34916247

Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database.

Riad Salem1, Ahmed Gabr2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34916247      PMCID： PMC8717188          DOI： 10.2967/jnumed.121.262917

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  13 in total

1.  Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.

Authors:  Etienne Garin; Lambros Tselikas; Boris Guiu; Julia Chalaye; Julien Edeline; Thierry de Baere; Eric Assenat; Vania Tacher; Corentin Robert; Marie Terroir-Cassou-Mounat; Denis Mariano-Goulart; Giuliana Amaddeo; Xavier Palard; Antoine Hollebecque; Marilyne Kafrouni; Hélène Regnault; Karim Boudjema; Serena Grimaldi; Marjolaine Fourcade; Hicham Kobeiter; Eric Vibert; Samuel Le Sourd; Lauranne Piron; Danièle Sommacale; Sophie Laffont; Boris Campillo-Gimenez; Yan Rolland
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-11-06

2.  Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.

Authors:  Andrew C Gordon; Ahmed Gabr; Ahsun Riaz; Omar M Uddin; Nadine Abouchaleh; Rehan Ali; Joseph Kallini; Riad Salem; Robert J Lewandowski
Journal:  Cardiovasc Intervent Radiol       Date:  2018-06-12       Impact factor: 2.740

3.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

4.  Observing Durable Responses and a Prolonged Survival Tail in Advanced Hepatocellular Carcinoma with Portal Vein Invasion Treated with Y90 Radioembolization.

Authors:  Yaqoob Qaseem; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2020-06-03       Impact factor: 2.740

5.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

6.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Authors:  Valérie Vilgrain; Helena Pereira; Eric Assenat; Boris Guiu; Alina Diana Ilonca; Georges-Philippe Pageaux; Annie Sibert; Mohamed Bouattour; Rachida Lebtahi; Wassim Allaham; Hélène Barraud; Valérie Laurent; Elodie Mathias; Jean-Pierre Bronowicki; Jean-Pierre Tasu; Rémy Perdrisot; Christine Silvain; René Gerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Frédéric Oberti; Olivier Couturier; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sarran; Charlotte Costentin; Emmanuel Itti; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Maxime Ronot; Aurelia Dinut; Laurent Castera; Gilles Chatellier
Journal:  Lancet Oncol       Date:  2017-10-26       Impact factor: 41.316

7.  Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.

Authors:  Ahmed Gabr; Laura Kulik; Samdeep Mouli; Ahsun Riaz; Rehan Ali; Kush Desai; Ronald A Mora; Daniel Ganger; Haripriya Maddur; Steven Flamm; Justin Boike; Christopher Moore; Bartley Thornburg; Ali Alasadi; Talia Baker; Daniel Borja-Cacho; Nitin Katariya; Daniela P Ladner; Juan Carlos Caicedo; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2020-11-07       Impact factor: 17.425

Review 8.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

9.  Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: Analysis of the US National Cancer Database.

Authors:  Joseph C Ahn; Marie Lauzon; Michael Luu; Marc L Friedman; Kambiz Kosari; Nicholas Nissen; Shelly C Lu; Lewis R Roberts; Amit G Singal; Ju Dong Yang
Journal:  J Nucl Med       Date:  2021-04-09       Impact factor: 11.082

10.  Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.

Authors:  Riad Salem; Guy E Johnson; Edward Kim; Ahsun Riaz; Vivian Bishay; Eveline Boucher; Kirk Fowers; Robert Lewandowski; Siddharth A Padia
Journal:  Hepatology       Date:  2021-06-11       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.